Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Also known as: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma / Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck / Recurrent, metastatic Head and Neck Squamous Cell Carcinoma / Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC) / Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma / Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck / Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck / Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck / Metastatic or Recurrent HNSCC
Drug | Drug Name | Drug Description |
---|---|---|
DB09035 | Nivolumab | A PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma. |
Drug | Drug Name | Target | Type |
---|---|---|---|
DB09035 | Nivolumab | Programmed cell death protein 1 | target |
DB09035 | Nivolumab | Programmed cell death 1 ligand 1 | target |
Drug | Drug Name | Phase | Status | Count |
---|---|---|---|---|
DB09037 | Pembrolizumab | 1 / 2 | Recruiting | 1 |
DB15155 | Pepinemab | 1 / 2 | Recruiting | 1 |
DB12015 | Alpelisib | 2 | Unknown Status | 1 |
DB00958 | Carboplatin | 2 | Recruiting | 1 |
DB00002 | Cetuximab | 2 | Recruiting | 1 |
DB00515 | Cisplatin | 2 | Completed | 1 |
DB00515 | Cisplatin | 2 | Recruiting | 1 |
DB17456 | Dalpiciclib | 2 | Recruiting | 1 |
DB01248 | Docetaxel | 2 | Completed | 2 |
DB00441 | Gemcitabine | 2 | Recruiting | 1 |
DB06186 | Ipilimumab | 2 | Completed | 1 |
DB17407 | MRG-003 | 2 | Recruiting | 1 |
DB06192 | Nimotuzumab | 2 | Not Yet Recruiting | 1 |
DB09035 | Nivolumab | 2 | Completed | 1 |
DB01229 | Paclitaxel | 2 | Recruiting | 1 |
DB01269 | Panitumumab | 2 | Completed | 2 |
DB09037 | Pembrolizumab | 2 | Recruiting | 1 |
DB15765 | Sintilimab | 2 | Not Yet Recruiting | 1 |